Vertex Pharmaceuticals, Inc.

Alios Biopharma, Inc.

Tara Lynn Kieffer

Chao Lin

Ann Kwong

Christoph Sarrazin

Leonid Beigelman

David Bernard Smith

Lawrence M Blatt

Yi Zhou

Julian Alexander Symons

Min Jiang

Ann Dak-Yee Kwong

Hua Tan

James Daniel Frantz

Douglas John Bartels

Judith A Lippke

Eileen Z Zhang

James C Sullivan

Cornelis Arie Rijnbrand

Benjamin Shames

Sheila Seepersaud

Christoph c/o JW Goethe University Hospital Frankfurt Sarrazin

Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.

Pharmaceutical combinations comprising a thionucleotide analog

A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

Methods for amplifying hepatitis C virus nucleic acids

The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

Hepatitis C virus variants

Growing community of inventors

Brookline, MA, United States of America

Tara Lynn Kieffer